Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
Cremer S, Pilgram L, Berkowitsch A, Stecher M, Rieg S, Shumliakivska M, Bojkova D, Wagner JUG, Aslan GS, Spinner C, Luxán G, Hanses F, Dolff S, Piepel C, Ruppert C, Guenther A, Rüthrich MM, Vehreschild JJ, Wille K, Haselberger M, Heuzeroth H, Hansen A, Eschenhagen T, Cinatl J, Ciesek S, Dimmeler S, Borgmann S, Zeiher A; LEOSS study group.
Cremer S, et al. Among authors: heuzeroth h.
PLoS One. 2021 Oct 21;16(10):e0258684. doi: 10.1371/journal.pone.0258684. eCollection 2021.
PLoS One. 2021.
PMID: 34673795
Free PMC article.